BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16534481)

  • 1. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty.
    Birnbaum F; Reis A; Böhringer D; Sokolowska Y; Mayer K; Voiculescu A; Oellerich M; Sundmacher R; Reinhard T
    Transplantation; 2006 Mar; 81(5):767-72. PubMed ID: 16534481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study.
    Birnbaum F; Mayweg S; Reis A; Böhringer D; Seitz B; Engelmann K; Messmer EM; Reinhard T
    Eye (Lond); 2009 Nov; 23(11):2063-70. PubMed ID: 19151659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study.
    Szaflik JP; Major J; Izdebska J; Lao M; Szaflik J
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):307-14. PubMed ID: 26553197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial.
    Reinhard T; Reis A; Böhringer D; Malinowski M; Voiculescu A; Heering P; Godehardt E; Sunmacher R
    Graefes Arch Clin Exp Ophthalmol; 2001 Jun; 239(5):367-72. PubMed ID: 11482341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study.
    Reinhard T; Mayweg S; Sokolovska Y; Seitz B; Mittelviefhaus H; Engelmann K; Voiculescu A; Godehardt E; Sundmacher R
    Transpl Int; 2005 Jun; 18(6):703-8. PubMed ID: 15910297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study.
    Mayer K; Reinhard T; Reis A; Voiculescu A; Sundmacher R
    Graefes Arch Clin Exp Ophthalmol; 2003 Dec; 241(12):1051-4. PubMed ID: 12928902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial.
    Reis A; Reinhard T; Voiculescu A; Kutkuhn B; Godehardt E; Spelsberg H; Althaus C; Sundmacher R
    Br J Ophthalmol; 1999 Nov; 83(11):1268-71. PubMed ID: 10535855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mycophenolate mofetil after penetrating high risk keratoplasty. A pilot study].
    Reinhard T; Reis A; Kutkuhn B; Voiculescu A; Sundmacher R
    Klin Monbl Augenheilkd; 1999 Sep; 215(3):201-2. PubMed ID: 10528287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study.
    Birnbaum F; Böhringer D; Sokolovska Y; Sundmacher R; Reinhard T
    Transplantation; 2005 Apr; 79(8):964-8. PubMed ID: 15849551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk.
    Chatel MA; Larkin DF
    Am J Ophthalmol; 2010 Aug; 150(2):179-84. PubMed ID: 20570235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basiliximab following penetrating risk-keratoplasty--a prospective randomized pilot study].
    Birnbaum F; Jehle T; Schwartzkopff J; Sokolovska Y; Böhringer D; Reis A; Reinhard T
    Klin Monbl Augenheilkd; 2008 Jan; 225(1):62-5. PubMed ID: 18236372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes of High-Risk Keratoplasty in Patients Receiving Systemic Immunosuppression.
    Chow SP; Cook SD; Tole DM
    Cornea; 2015 Nov; 34(11):1395-9. PubMed ID: 26382894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation.
    Groetzner J; Wittwer T; Kaczmarek I; Ueberfuhr P; Strauch J; Nagib R; Meiser B; Franke U; Reichart B; Wahlers T
    Transplantation; 2006 Feb; 81(3):355-60. PubMed ID: 16477220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
    Sampaio EL; Pinheiro-Machado PG; Garcia R; Felipe CR; Park SI; Casarini DE; Moreira S; Franco MF; Tedesco-Silva H; Medina-Pestana JO
    Clin Transplant; 2008; 22(2):141-9. PubMed ID: 18339132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inferior results with basis immunosuppression with sirolimus in kidney transplantation.
    van den Akker JM; Hené RJ; Hoitsma AJ
    Neth J Med; 2007 Jan; 65(1):23-8. PubMed ID: 17293636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model.
    Birnbaum F; Schwartzkopff J; Scholz C; Reis A; Reinhard T
    Eye (Lond); 2007 Dec; 21(12):1516-23. PubMed ID: 17401326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.